BIOVERATIV
Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies.
BIOVERATIV
Industry:
Biotechnology
Founded:
2016-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.bioverativ.com
Total Employee:
251+
Status:
Closed
Contact:
(781)663-4400
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving Apache Amazon IPv6 JQuery CDN Microsoft GoDaddy SSL Vimeo Shutterstock GlobalSign
Similar Organizations
NovelMed Therapeutics
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.
RetroVirox
RetroVirox is a privately-held biotechnology company dedicated to discovering new treatments for patients with infectious diseases
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-05-23 | True North Therapeutics | True North Therapeutics acquired by Bioverativ | 400 M USD |
More informations about "Bioverativ"
Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 22, 2006 Sanofi's R&D organization will support Bioverativ in bringing these important therapies to patients faster. Furthermore, Sanofi's global presence, proven expertise and …See details»
Bioverativ - Crunchbase Company Profile & Funding
Organization. Bioverativ . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Bioverativ is a global biotechnology company …See details»
Sanofi Completes Acquisition of Bioverativ Inc.
Paris (France) - March 8, 2018 - Sanofi announced today the successful completion of its acquisition of Bioverativ Inc. ("Bioverativ") for $105 per share in cash. "The addition of …See details»
Bioverativ Stockholder Settlement
The Court directed that everyone who fits this description is a Settlement Class Member: Any and all holders of Bioverativ Inc. common stock, either of record or beneficially, at any time during …See details»
Bioverativ Inc. Company Profile | Waltham, MA - Dun & Bradstreet
Company Description: Bioverativ is a biotechnology firm focused on discovering, developing, and commercializing treatments for hemophilia and other rare blood disorders. It has two products …See details»
Bioverativ, a Sanofi company - LinkedIn
Bioverativ, a Sanofi company, is dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development, and commercialization …See details»
Bioverativ Company Profile - Office Locations, Competitors ... - Craft
Bioverativ is a biotechnology company that is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. …See details»
Sanofi to Acquire Bioverativ
Bioverativ is a Biotechnology Company with a Leading Hemophilia Presence •Bioverativ is a Biotech company that develops transformative therapies for rare blood disorders • …See details»
Bioverativ, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Dec 13, 2024 John Cox, the then-CEO of Bioverativ, said at the time that Enjaymo was a central asset in the deal and filled an important gap in the companys research efforts.Enjaymo, …See details»
Bioverativ - Contacts, Employees, Board Members, Advisors
Bioverativ is a global biotechnology company dedicated to transforming the lives of people living with hemophilia and other blood disorders. ... Solutions. Products. Resources. Pricing. …See details»
Sanofi Buys Bioverativ - Pharma's Almanac
Jan 23, 2018 The French drugmaker expands its presence in blood disorders and rare diseases. In the largest acquisition by the French organization in seven years, Sanofi SA has agreed to …See details»
Bioverativ Canada Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Bioverativ Canada Inc. of Calgary, AB. Get the latest business insights from Dun & Bradstreet.See details»
Sanofi digs deep to buy US hemophilia specialist Bioverativ for …
Jan 22, 2018 Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years.See details»
Activist investor Alex Denner, Bioverativ shareholder reach ... - STAT
Apr 29, 2024 A tentative settlement has been reached in a long-running shareholder lawsuit that accused health care activist investor Alex Denner of making nearly $50 million from insider …See details»
Sanofi to buy US biotech group Bioverativ for $11.6bn - Financial …
Jan 22, 2018 Sanofi. has confirmed it is to buy Bioverativ, a US biotech group focused on haemophilia treatments, for $11.6bn, putting an end to the French drugmaker’s long quest for …See details»
Sanofi's Bioverativ deal begins to pay dividends with first new drug ...
Feb 7, 2022 The Bioverativ deal was among those pursuits, giving Sanofi two marketed hemophilia drugs known as Eloctate and Alprolix and other rare disease treatments in various …See details»
Biogen Announces Bioverativ as Name of New Hemophilia …
Aug 9, 2016 Bioverativ will also focus on advancing pipeline programs that address areas of unmet need in hemophilia and other blood disorders, including programs studying longer …See details»
Sanofi to Acquire Bioverativ for $11.6 Billion - GlobeNewswire
Jan 22, 2018 Sanofi's R&D organization will support Bioverativ in bringing these important therapies to patients faster. Furthermore, Sanofi's global presence, proven expertise and …See details»
Bioverativ taps new manufacturer as it steps out of Biogen's shadow
Feb 15, 2018 When Bioverativ officially split off from Biogen Inc. early last year, for instance, the smaller drugmaker agreed to a production and supply deal under which its former parent …See details»